Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Feature

Emerging Molecular Targets to Treat Disorders Affecting Cognitive Function

Posted on: 03 Feb 04

Summary

Pharmaceutical Education Associates’ presents a one-of-a-kind forum exploring the most recent and clinically relevant research pertaining to brain targets for the enhancement of cognitive function. Of particular interest will be the effectiveness of new cognition-enhancing drugs in the treatment of neurodegenerative disorders such as Alzheimer’s disease, as well as their potential for the treatment of the cognitive decline associated with normal aging or as a prelude to disease.

Emerging Molecular Targets to Treat Disorders Affecting Cognitive Function

May 17-18, 2004

The Westin Princeton at Forrestal Village

 

About this Conference

 

Pharmaceutical Education Associates’ presents a one-of-a-kind forum exploring the most recent and clinically relevant research pertaining to brain targets for the enhancement of cognitive function. Leading researchers will share findings obtained from animal models and clinical studies in which drugs have been targeted to cholinergic, glutamatergic, GABAergic, histaminergic, and specific second messenger pathways, as well as KCNQ potassium channels. Of particular interest will be the effectiveness of new cognition-enhancing drugs in the treatment of neurodegenerative disorders such as Alzheimer’s disease, as well as their potential for the treatment of the cognitive decline associated with normal aging or as a prelude to disease.

 

Among the cutting-edge presentations you’ll hear are:

 

*Exploring the PDE-4/CREB Pathway

Tim Tully, Helicon Therapeutics

 

*GABA-B antagonists: Preclinical and Clinical Profile of SGS742, a novel GABA-B receptor antagonist

Thorsten Melcher, Saegis Pharmaceuticals, Inc.

 

*AMPA Receptor Modulation

Gary Rogers, Cortex Pharmaceuticals

 

*H3 Antagonists: Broad Preclinical Efficacy in Cognition and Schizophrenia

Gerard Fox, Abbott Laboratories

 

*TC-1734: An Orally Active Neuronal Nicotinic Receptor Modulator and Long-Lasting Cognitive Enhancing Properties and Neuroprotective Properties

Gregory Gatto, Targacept, Inc.

 

*KCNQ Channels as Potential Targets for the Treatments of Cognitive Diseases

William Dalby Brown, Neurosearch A/S (Denmark)

 

*M1 Muscarinic Agonists: Their Therapeutic Potential in Alzheimer’s Disease (AD) and Related Diseases

Abraham Fisher, Israel Institute for Biological Research, Ness Ziona, Israel

 

PLUS: A Special Workshop: Overcoming the Blood Brain Barrier in CNS Drug Delivery”

Part I: The Blood-brain Barrier and Delivery of Drug and Gene Therapeutics to the CNS

Part II: Intranasal Drug Delivery to the CNS

 

Presenter, Parts I and II : William H. Frey, II, Alzheimer’s Research Center, Regions Hospital and University of Minnesota

 

Part III: Peptide Transport Across the Blood-Brain Barrier

Weihong Pan, Tulane University and VA Medical Center

 

This event is truly a must-attend chance to hear the latest research in the rapidly growing field of cognitive enhancing drugs.

 

To register, call 800-686-2276 or click to register here http://www.pharmedassociates.com/rand.asp#p166

Jennifer McGinnis

Last updated on: 27/08/2010 11:40:18

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.